Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Ray

Showing results (151-160 of 229) with videos related to

Pageof 23
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2011
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcomeN Penel, A Italiano, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†N Colombo, C Sessa, A du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseN Colombo, C Sessa, A du Bois, et al.
ESMO Open|January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancersJ-Y Blay, M Brahmi, A Dufresne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
ESMO Open|June 5, 2025
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trialL Collet, J-C Noël, X Catteau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trialB Bui-Nguyen, I Ray-Coquard, C Chevreau, et al.
European Journal of Cancer (Oxford, England : 1990)|January 30, 2016
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)T Valentin, A Le Cesne, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2010
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upN Penel, A Le Cesne, B N Bui, et al.
Bulletin Du Cancer|December 25, 2007
[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment]C Lhommé, F Planchamp, F Joly, et al.
Pageof 23

Showing results (151-160 of 229) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2011
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcomeN Penel, A Italiano, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†N Colombo, C Sessa, A du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseN Colombo, C Sessa, A du Bois, et al.
ESMO Open|January 4, 2025
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancersJ-Y Blay, M Brahmi, A Dufresne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
ESMO Open|June 5, 2025
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trialL Collet, J-C Noël, X Catteau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trialB Bui-Nguyen, I Ray-Coquard, C Chevreau, et al.
European Journal of Cancer (Oxford, England : 1990)|January 30, 2016
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)T Valentin, A Le Cesne, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2010
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upN Penel, A Le Cesne, B N Bui, et al.
Bulletin Du Cancer|December 25, 2007
[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment]C Lhommé, F Planchamp, F Joly, et al.
Pageof 23